E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma

Chiao-Yun Lin An-Shine Chao Shih-Ming Jung Ren-Chin Wu Ting-Chang Chang Yun-Shien Lee Yun-Hsin Tang Shih-Sin Huang A. Chao C. Lai

Aug 2026 · Cancer Gene Therapy · Vol 33, pp. 1099 - 1112 · 0 citations · 50 references

Medicine

TL;DR

Findings identify the E-cadherin/IL-6/autophagy axis as a key mediator of platinum resistance in ovarian cancer.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Aug 2026

Hypoxia drives ERO1A-dependent angiogenesis in ovarian cancer cells promotes peritoneal metastasis and platinum resistance

High-grade serous ovarian cancer (HGSOC) is characterized by early peritoneal dissemination and frequent platinum resistance, yet the epithelial states and mechanisms that couple metastasis, angiogenesis, and therapy response remain incompletely defined. We integrated in-house single-cell RNA sequencing of 82,149 cel...

Si-Yang Zhang, Yu-Tong Liu, Xinyi Wang et al. · Cell Death & Disease · 0 citations

Open access Aug 2026

IL20RB drives non-small cell lung cancer progression and immune evasion via K267‑dependent activation of JAK2 phosphorylation and STAT3 signaling.

Pharmacologic suppression of IL20RB by APAP presents a novel therapeutic strategy, positioning IL20RB as a promising prognostic biomarker and therapeutic target in NSCLC.

Yang-Hao Wang, Guo-Yun Li, Wei-Zhou Wang et al. · Lung Cancer · 0 citations

Sep 2026

E2F1-mediated transcriptional regulation of TMEM33 promotes colorectal cancer proliferation, metastasis, and EMT

Silencing of TMEM33 markedly suppresses CRC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) both in vitro and in vivo, and significantly reduces subcutaneous tumor growth and pulmonary metastatic burden.

Rui Li, Li Zhao, Nan-Nan Chai et al. · Human Cell · 0 citations

Sep 2026

c-MET/NF-κB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer.

BACKGROUND c-MET overexpression is common in non-small cell lung cancer (NSCLC) and associated with poor prognosis, however, its role in immune evasion and immunotherapy resistance remains unclear. METHODS We analyzed c-MET expression in public "The Cancer Genome Atlas NSCLC" cohort (n = 1043) and an institutional co...

Li-Jin Chen, Xi-Hu Yao, Chun-Yan Su et al. · International Immunopharmaco... · 0 citations

Open access 2026

LINC00460 drives clear cell renal cell carcinoma progression via complement/coagulation and p53 pathways: a potential therapeutic target.

Findings establish LINC00460 as an oncogenic driver in ccRCC and a promising target for both diagnosis and precision therapy and identifies cinchonine and iproniazid as candidate therapeutic agents.

Bo Dong, Songtao Liu, Wenyu Wang et al. · American journal of translat... · 0 citations

Open access 2026

Transcriptional activation of ALOX5 by c-Myc drives malignant progression and M2 macrophage polarization in clear cell renal cell carcinoma.

It is suggested that the c-Myc-ALOX5 pathway promotes ccRCC progression by enhancing tumor cell aggressiveness and M2 macrophage polarization, offering a potential therapeutic target for immune microenvironment modulation in renal cancer.

Chang-Jie Ren, Yi-Jun Tian, Xin-Ran Zhang et al. · American Journal of Cancer R... · 0 citations